CSIMarket
 
Livanova Plc  (NASDAQ: LIVN)
 
Price: $80.1600 $0.35 0.439%
Day's High: $80.625 Week Perf: 0.24 %
Day's Low: $ 78.49 30 Day Perf: -2.79 %
Volume (M): 585,411 52 Wk High: $ 85.76
Volume (M$): $ 0 52 Wk Avg: $66.23
Open: $79.57 52 Wk Low: $48.82



 Market Capitalization (Millions $) 4,484
 Shares Outstanding (Millions) 56
 Employees 3,300
 Revenues (TTM) (Millions $) 1,432
 Net Income (TTM) (Millions $) 107
 Cash Flow (TTM) (Millions $) -199
 Capital Exp. (TTM) (Millions $) 85

Business Description


Livanova Plc is a diversified medical technology company that is committed to improving patient outcomes and reducing the cost of healthcare in the areas of cardiovascular and neuromodulation treatment. The company was formed in 2015, as a result of a merger between Cyberonics Inc. and Sorin Group.

Headquartered in London, Livanova operates in over 100 countries worldwide, with its primary focus being on the development, manufacture, and marketing of medical devices used in the treatment of various heart and neurological conditions. It has over 3,500 employees working across its various manufacturing and research facilities in the United States, Europe, and Asia-Pacific.

Livanovaes Cardiovascular business segment offers a range of products that include heart-lung equipment, oxygenators, perfusion systems, cannulae, and devices used in extracorporeal membrane oxygenation (ECMO) therapy. Its pioneering ECMO technology is widely recognized and used for treating life-threatening cardiopulmonary failure in neonatal and pediatric patients. The companyes implantable cardiac rhythm management products, including pacemakers, defibrillators, and cardiac resynchronization therapy devices, are designed to manage cardiac arrhythmias and heart failure.

The Neuromodulation business segment of Livanova provides products for the treatment of patients with epilepsy, depression, chronic pain, and other neurological disorders. Its Vagus Nerve Stimulation (VNS) Therapy System is a revolutionary device that delivers electrical stimulation to the vagus nerve, offering relief to patients with epilepsy and depression who have not responded to traditional treatments. The segment also produces Deep Brain Stimulation (DBS) Systems, which can reduce symptoms of movement disorders such as Parkinsones disease.

Livanova Plc is dedicated to research and development, with a strong pipeline of new products and technological innovation. They continually invest in research and development and have a strong focus on profitability and growth. They have a strong corporate culture, and their core values include focusing on patients, working collaboratively, continuous improvement, and maintaining a high level of ethical conduct.

In conclusion, Livanova Plc is a global leader in the development and manufacture of medical technology that improves the lives of people with heart and neurological conditions. With a dedicated team, strong product pipeline, and a commitment to innovation, Livanova is well-positioned to grow in the medical device market for many years to come.


   Company Address: 20 Eastbourne Terrace London 0
   Company Phone Number: 203 325-0660   Stock Exchange / Ticker: NASDAQ LIVN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -3.08%    
BDX   -1.4%    
BSX   -3.57%    
EW   -0.14%    
SYK   -3.99%    
ZBH   -0.84%    
• View Complete Report
   



Business Update

Bridging Breakthroughs LivaNova Fueled by CMS Backing in Epilepsy Care and Promising Sleep Apnea Study Results,

Published Mon, Nov 24 2025 4:22 PM UTC

LONDON LivaNova PLC (Nasdaq: LIVN), a leading force in medical technology, has marked significant milestones with advancements in its neuromodulation therapies. The U.S. Centers for Medicare & Medicaid Services (CMS) recently assigned LivaNova’s Vagus Nerve Stimulation (VNS) Therapy a new classification, which is expected to boost reimbursement levels for procedures treati...

Business Update

for the LivaNovas Growth Journey Insights and Strategic Vision to be Unveiled at Wolfe Research Healthcar...

Published Thu, Oct 23 2025 1:49 PM UTC

LivaNova Showcases Growth and Strategic Insights at Wolfe Research Healthcare Conference LONDON, October 2023 LivaNova PLC (Nasdaq: LIVN), a prominent player in the medical technology sector, is set to showcase its growth trajectory and strategic direction at the upcoming Wolfe Research Healthcare Conference 2025. The conference will take place on November 17 in New York...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 40.90
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.13
Price to Sales (Expected) -
Price to Book 3.7
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.71
Working Capital Ratio 1.33
Leverage Ratio (MRQ) 1.08
Total Debt to Equity 0.24
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.48

Per Share Current
Earnings (TTM) 1.96 $
Revenues (TTM) 25.6 $
Cash Flow (TTM) -
Cash 9.65 $
Book Value 21.65 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 433,954
Net Income per Employee (TTM) 32,468
Receivable Turnover Ratio (TTM) 6.53
Inventory Turnover Ratio (TTM) 2.8
Asset Turnover Ratio (TTM) 0.56

Profitability Ratios Current
Gross Margin (MRQ) 67.38 %
Operating Margin (MRQ) 11.46 %
Net Margin (MRQ) 6.16 %
Net Cash Flow Margin (MRQ) -26.5 %
Effective Tax Rate (TTM) 11.71 %

Management Effectiveness Current
Return On Assets (TTM) 4.19 %
Return On Investment (TTM) 5.83 %
Return On Equity (TTM) 9.14 %
Dividend Yield -
Pay out Ratio (TTM) -



Livanova Plc's Segments
United States    51.05 % of total Revenue
Europe    20.91 % of total Revenue
Rest of World    28.18 % of total Revenue
Cardiopulmonary    57.68 % of total Revenue
Neuromodulation    41.96 % of total Revenue
United States Cardiopulmonary    19.15 % of total Revenue
United States Neuromodulation    31.9 % of total Revenue
Europe Cardiopulmonary    15.84 % of total Revenue
Europe Neuromodulation    5.07 % of total Revenue
Rest of World Cardiopulmonary    22.69 % of total Revenue
Rest of World Neuromodulation    4.99 % of total Revenue
Other    0.5 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.